In last trading session, Enliven Therapeutics Inc (NASDAQ:ELVN) saw 0.32 million shares changing hands with its beta currently measuring 1.02. Company’s recent per share price level of $21.74 trading at -$2.41 or -9.98% at ring of the bell on the day assigns it a market valuation of $1.06B. That closing price of ELVN’s stock is at a discount of -38.13% from its 52-week high price of $30.03 and is indicating a premium of 49.86% from its 52-week low price of $10.90. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.17 million shares which gives us an average trading volume of 217.58K if we extend that period to 3-months.
Enliven Therapeutics Inc (NASDAQ:ELVN) trade information
Upright in the red during last session for losing -9.98%, in the last five days ELVN remained trading in the red while hitting it’s week-highest on Friday, 01/03/25 when the stock touched $21.74 price level, adding 14.31% to its value on the day. Enliven Therapeutics Inc’s shares saw a change of -3.38% in year-to-date performance and have moved -9.04% in past 5-day. Enliven Therapeutics Inc (NASDAQ:ELVN) showed a performance of -10.97% in past 30-days. Number of shares sold short was 6.87 million shares which calculate 37.47 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 39.5 to the stock, which implies a rise of 44.96% to its current value. Analysts have been projecting 39 as a low price target for the stock while placing it at a high target of 40. It follows that stock’s current price would drop -79.39% in reaching the projected high whereas dropping to the targeted low would mean a loss of -79.39% for stock’s current value.
Enliven Therapeutics Inc (ELVN) estimates and forecasts
Statistics highlight that Enliven Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -9.64% of value to its shares in past 6 months, showing an annual growth rate of 2.99% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 5.16% during past 5 years.
Enliven Therapeutics Inc (NASDAQ:ELVN)’s Major holders
Insiders are in possession of 6.39% of company’s total shares while institution are holding 98.75 percent of that, with stock having share float percentage of 105.50%. Investors also watch the number of corporate investors in a company very closely, which is 98.75% institutions for Enliven Therapeutics Inc that are currently holding shares of the company.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.08 shares of worth $23.44 million or 2.21% of the total outstanding shares. The later fund manager was in possession of 905.62 shares on Oct 31, 2024 , making its stake of worth around $19.69 million in the company or a holder of 1.85% of company’s stock.
